AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03912415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (or Carboplatin)
Description: IV infusion
Study NCT01155726 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens with comfort additive (1DAVM), partially masked
Description: Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
Study NCT02689856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate and lidocaine hydrochloride
Description: Hydrocortisone and lidocaine in combination
Study NCT02689856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Vehicle cream alone
Study NCT02689856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate
Description: hydrocortisone alone
Study NCT02689856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: lidocaine alone
Study NCT02873299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10 Hz rTMS of the right dorsolateral prefrontal cortex
Description: Ten sessions of 10 Hz rTMS of the right dorsolateral prefrontal cortex
Study NCT03912415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin (or Carboplatin)
Description: IV infusion
Study NCT03912415 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02553915 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soybean oil placebo
Study NCT02873299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20 Hz rTMS of the right dorsolateral prefrontal cortex
Description: Ten sessions of 20 Hz rTMS of the right dorsolateral prefrontal cortex
Study NCT04616274 — intervention group
Intervention type: DRUG
Intervention: Venetoclax
Description: This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
Study NCT02880449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A PA promoting intervention which provides education, social support and information about local opportunities for PA to pre-existing groups of older women living in socio-economically disadvantaged areas
Study NCT02382510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN-157
Study NCT02382510 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02382510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study NCT01912820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract
Description: Given PO
Study NCT01912820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: green tea extract
Description: Given PO
Study NCT01912820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quercetin
Description: Given PO
Study NCT01912820 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01912820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo prostatectomy
Study NCT01912820 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo prostatectomy
Study NCT01912820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01912820 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00050414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 0.58 mg/m2, administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression.
Study NCT00050414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
Study NCT00047710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).
Study NCT00047710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 650mg/m\^2 taken by mouth twice a day 15-52 during the radiotherapy.
Study NCT00047710 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.
Study NCT01946243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F18
Description: No Florbetapir F 18 will be administered in this study.
Study NCT02553915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA 1 g/day
Description: Omega-3 fatty acid extracted from fish oil, 1 g/day
Study NCT02553915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA 2 g/day
Description: Omega-3 fatty acid extracted from fish oil, 2 g/day
Study NCT02553915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA 4 g/day
Description: Omega-3 fatty acid extracted from fish oil, 4 g/day
Study NCT01748695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V158866
Study NCT03578822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human urokinase
Description: Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
Study NCT03578822 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Aspirin 300mg is taken orally at the beginning of thrombolysis.
Study NCT03578822 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rhPro-UK simulation agent
Description: Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
Study NCT03578822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin simulation agent
Description: Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
Study NCT04980105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Two intra-articular injections of autologous platelets-rich plasma (PRP) in two weeks intervals between the first and the second injection.
Study NCT04980105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Two intraarticular injections of hyaluronic acid (60 mg) in two weeks intervals between the first and the second injection
Study NCT04980105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)
Description: Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
Study NCT05262322 — intervention group
Intervention type: DRUG
Intervention: Edoxaban
Description: This was a non-interventional, observational study. No drug was administered in this study.
Study NCT05262322 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: This was a non-interventional, observational study. No drug was administered in this study.
Study NCT05262322 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: This was a non-interventional, observational study. No drug was administered in this study.
Study NCT01748695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03345043 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAL-339851
Description: Escalating dose levels
Study NCT03345043 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT02375750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GBO and GBG
Description: Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
Study NCT02375750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
Study NCT01949922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of autologous muscle fibers into the anal sphincter.
Study NCT01949922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.
Study NCT01949922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.
Study NCT01949922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesia
Description: Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
Study NCT01968369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: tomato sauce
Description: We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
Study NCT03255499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise
Study NCT03255499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive
Description: Cognitive
Study NCT03255499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Active control, including a blend of computer games, board games, quizzes, trivia
Study NCT01968369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tomato sauce
Description: We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
Study NCT04388787 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stochastic resonance (SR) wraps
Description: SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.
Study NCT04388787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance (SR) wraps
Description: SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.
Study NCT04202757 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: [21CFR640.30] Plasma from 18 - 25 year old volunteer donors
Description: 12.5 ml/kg intravenous Spectrum Plasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
Study NCT02961582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral Neuromodulation
Description: SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted.~Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient.
Study NCT02961582 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Personalized Conservative Treatment
Description: The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
Study NCT04093882 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast agent enhanced MRI using Gadovist
Description: By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
Study NCT01121354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin 2g for Injection USP and Dextrose Injection USP
Description: Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
Study NCT01121354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin 1.5g
Description: Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
Study NCT02957227 — intervention group
Intervention type: DEVICE
Intervention: No intervention is part of this study but patients use an EEG device during observational data collection.
Study NCT01743703 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: diagnostic whole body MRI
Description: diagnostic whole body MRI, both STIR and diffusion weighted
Study NCT03630510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation
Description: The ventilator hyperinflation maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
Study NCT01688401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan hydrochloride
Description: Drug administered intra-arterially (injection in the artery).~Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.~Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks.
Study NCT00618566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WPD and Depression Treatment Group
Description: Intervention selected will depend on Phase I data analysis.
Study NCT01152385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet administered twice daily during 4 months
Study NCT01152385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered twice daily during 4 months
Study NCT03548090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 5 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (5 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
Study NCT05450120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Rehabilitation
Description: Functional rehabilitation protocol
Study NCT03548090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight
Description: Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
Study NCT05450120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Rehabilitation
Description: Functional rehabilitation protocol
Study NCT05450120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Neuromuscular electrical stimulation protocol
Study NCT02610023 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
Study NCT02149797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four port laparoscopic cholecystectomy
Description: Classical four port laparoscopic cholecystectomy
Study NCT02149797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILC-Pick'n roll-Beginning (group I)
Description: SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a half-knot. The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided
Study NCT02149797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILC-Pick'n roll-Experienced (group II)
Description: Similar technique of SILC-Pick'n roll-Beginning (group I) was used
Study NCT03177070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
Study NCT02758080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching on the basis of molecular analysis
Study NCT02758080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Matching on the basis of physician's choice
Study NCT01183182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiSight Needle Guidance System
Description: Three different groups of patients defined per lesion size
Study NCT02610023 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02610023 — intervention group
Intervention type: DEVICE
Intervention: Spectroscopy
Description: Undergo resonance Raman spectroscopy
Study NCT04806568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The cognitive training treatment is a Greek adaptation of BrainHQ developed by Posit Science Corporation. The intervention will target speed, attention, working memory, and executive function through the visual and auditory domains via a set of 15 exercises. Each daily training session consists of four exercises chosen from an active set of six. Participants will be instructed to train for one hour per day, three days per week, over 12 weeks via a tablet. Each subject will receive at least 29 sessions of computerized cognitive training.
Study NCT04806568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring of daily activity
Description: Monitoring of daily activity via Fitbit Charge 4 smartwatch.
Study NCT04806568 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of daily activity
Description: Monitoring of daily activity via Fitbit Charge 4 smartwatch.